Company Overview and News

Stop missing out on important events!

Fintel provides real time notifications of important company events such as major investments (13D/G filings), insider trades (SEC form 4), and important SEC filings. Sign up and create your company alerts for free.

Headline News

Geron's Imetelstat Hits A Grand Slam, But The Rally Is Just Beginning

2018-03-21 seekingalpha
Geron (GERN) issued an 8-K on Friday which revealed more details than expected on the company's two ongoing Phase II trials with their lead candidate Imetelstat. The news was cheered by investors, but this is only the beginning. There are a number of catalysts that could see Geron achieve a multiple of the current market price. (162-0)

You Didn't Have To Let JNUG Get You Down

2018-03-21 seekingalpha
Last month, I suggested avoiding JNUG because it failed the first of Portfolio Armor's two screens. I suggested readers consider my site's top ten names instead. (111-0)

Biotechs Approaching New Waters

2018-03-20 seekingalpha
The biotech sector also continues to benefit from potential M&A, faster drug approvals, strong risk appetite, and improving public sentiment. (727-2)

BRIEF-AbbVie Says CEO's 2017 Total Compensations Were $22.63 Mln Vs $20.97 Mln In 2016

2018-03-19 reuters

ABBV / AbbVie Inc. DEF 14A

Use these links to rapidly review the document Table of Contents CD&A Table of Contents (66-0)

ABBV / AbbVie Inc. DEFA14A


J&J Gets $2.1B Offer for LifeScan Diabetes Device Unit

2018-03-19 zacks
Johnson & Johnson (JNJ - Free Report) announced that it has received a binding offer of approximately $2.1 billion from a private equity firm, Platinum Equity, for its LifeScan diabetes device unit. The LifeScan unit makes blood glucose monitoring products and generated revenues of $1.5 billion last year. (95-0)

Biotech Bio Series #2: Is Gilead Still A Growth Stock?

2018-03-19 seekingalpha
HIV is a bright spot for Gilead but sales growth does not come close to replacing revenue lost from HCV. (88-0)

Jefferies Adds Red-Hot Retail Stock to Franchise Picks List

2018-03-19 247wallst
All Wall Street firms we follow here at 24/7 Wall St. keep a list for their institutional and retail clients of high-conviction stock picks. These are generally the stocks they not only like on a longer term basis, but those that usually have big upside to the assigned target price. Since the beginning of the year, many analysts have tweaked their lists to account for potential changes in 2018, and one company has added a new stock we feel could have outsized upside potential. (133-0)

Biogen's Key Variable: Its Neuroscience Pipeline

2018-03-18 seekingalpha
Biogen (NASDAQ:BIIB) is best known for its MS (multiple sclerosis) therapies. While Biogen is set to remain a major player in that setting, its future expansion will likely be in other neural diseases. (165-0)

Why Multiple Sclerosis is a Promising but Risky Space?

2018-03-16 zacks
The Multiple Sclerosis (MS) space hit the headlines once again following biotech bigwig, Biogen (BIIB - Free Report) and partner AbbVie’s (ABBV - Free Report) decision to withdraw their jointly owned MS drug, Zinbryta voluntarily on a worldwide basis due to risk of liver injury. Both companies decided to withdraw the drug on grounds of the complex and evolving benefit/risk profile of Zinbryta, given the limited number of patients treated. (177-0)

Pharma Stock Roundup: ABBV's Elagolix Meets Study Goal, MRK's Keytruda in Focus

2018-03-16 zacks
This week was a relatively light one as far as developments in the pharma sector were concerned. The key highlights were priority review for Merck’s (MRK - Free Report) Keytruda for advanced cervical cancer, delay in final data from AstraZeneca’s (AZN - Free Report) key lung cancer study, success of AbbVie’s (ABBV - Free Report) another late stage study and breakthrough therapy designation for J&J’s (JNJ - Free Report) cancer candidate. (119-0)

Strong Buy for AbbVie (ABBV) This Week

2018-03-16 investorplace
At $114.93, AbbVie (ABBV) a Strong Buy based on the most recent SEC filings, and comparative pricing of its shares. AbbVie Inc's (NYSE:ABBV) Strong Buy recommendation is the outcome of a process of analysis that is proprietary and produced results that were above average in 4 areas: an economic sector ranked above average in attractiveness, a ranking in its sector group that is in the top decile, ranking in its industry group that is in the top decile, and a numerical calculation of risk/reward that is very attractive; and produced below average outcomes in 2 areas: an industry group rated below average in attractiveness, and analytical scores that are below average. (67-0)

3 Things In Biotech, March 15: AbbVie's Breakthrough, Bellicum Strikes Back, Sarepta's Guidance

2018-03-16 seekingalpha
Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. (67-0)

'Safer' Dividend Aristocrats Gain Best By Walmart, Mickey D, Procter, Leggett And Medtronic, Per March Targets

2018-03-15 seekingalpha
42 of 53 S&P 500 Dividend Aristocrats stocks were deemed "safer" for dividends because they showed positive one-year returns and free cash flow yields greater than their dividend yields 3/13/18. (133-0)

CUSIP: 00287Y109